このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

妊娠中の母親のためのより健康的な家庭の食事 (Her HOME)

2026年10月12日 更新者:Gareth R. Dutton PhD、University of Alabama at Birmingham

ハイリスク女性の過剰な妊娠中の体重増加を減らすための宅配食の使用

This study is being done to test the feasibility, acceptability, and preliminary efficacy of a meal delivery intervention for managing gestational weight gain among pregnant women with overweight or obesity.

調査の概要

状態

完了

介入・治療

研究の種類

介入

入学 (実際)

35

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35294
        • University of Alabama at Birmingham

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

女性

説明

Inclusion Criteria:

  • Age ≥ 18 years
  • Gestational age ≤ 15 weeks as assessed by ultrasound
  • Body mass index (BMI) ≥ 25 kg/m2
  • Singleton viable pregnancy
  • Receiving care and planning to deliver at UAB
  • Residing within the delivery radius of the meal delivery company
  • Wi-Fi or Bluetooth Internet connection in home (for digital Wi-Fi enabled study scale)

Exclusion Criteria:

  • Self-reported major health conditions (e.g., heart disease, cancer, renal disease, and Type 1 or Type 2 diabetes)
  • Current substance abuse
  • Current treatment for serious psychiatric disorder (schizophrenia, bipolar disorder)
  • Known fetal anomaly
  • Planned termination of pregnancy
  • Past history or current diagnosis of anorexia or bulimia
  • Current use of one or more of the following medications:
  • Metformin
  • Systemic steroids
  • Antipsychotic agents
  • Anti-seizure medications or mood stabilizers that would be expected to have a significant impact on body weight
  • Medications for ADHD including amphetamines and methylphenidate
  • Any teratogenic agent Class D
  • Participation in another dietary and/or weight management intervention during pregnancy
  • Unwilling or unable to consume prepared meals delivered weekly
  • Unable to understand and communicate in verbal and written English

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Intervention

Meal delivery intervention with brief behavioral support.

10 healthy, home-delivered meals per week + brief weekly remote behavioral support

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Weight From First to Last Prenatal Visit
時間枠:First prenatal visit (<=15 weeks gestation), last prenatal visit (35+ weeks gestation)

Weight measured at the first and last prenatal visits will be retrieved from medical records for all participants and used to calculate total weight change from the first to the last prenatal visit (i.e., gestational weight gain).

First prenatal visit (<=15 weeks gestation), last prenatal visit (35+ weeks gestation)

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in Food Insecurity
時間枠:baseline (12-15 weeks gestation), (35-36 weeks gestation)

Determined using the 18-item United States (US) Household Food Security Survey Module based on the previous 30 days. Adult food security scores range from 0 to 10, with lower values indicating greater food security. Change in Food Security was calculated as food security score at follow up minus score at baseline, with negative values indicating an increase in food security from baseline to follow up.

baseline (12-15 weeks gestation), (35-36 weeks gestation)
Change in Perceived Stress
時間枠:baseline (12-15 weeks gestation), (35-36 weeks gestation)

Determined using the 10-item Perceived Stress Scale (PSS-10) based on the last month. PSS-10 scores range from 0 to 40, with higher scores representing higher levels of perceived stress. Change in Perceived Stress score was calculated as score at follow up minus score at baseline, with positive values indicating an increase in perceived stress score from baseline to follow up.

baseline (12-15 weeks gestation), (35-36 weeks gestation)
Change in Participant Satisfaction With Diet
時間枠:baseline (12-15 weeks gestation), (35-36 weeks gestation)

To assess satisfaction with the study intervention, the 28-item Diet Satisfaction Questionnaire (DSAT-28) will be used in which participants respond to 28 statements using a 5-point Likert scale. Responses to all 28-items are averaged to produce a total diet satisfaction score (designed to reflect satisfaction as it relates to following a weight-management diet) ranging from 1-5. Subscale scores for Cost Factor (reflects financial cost of the diet) and Planning & Preparation Factor (reflects amount of time and effort spent in planning and preparing) will also be calculated and range from 1-5. For the overall diet satisfaction score and subscale scores, higher scores represent greater satisfaction. Changes in overall diet satisfaction, as well as changes in subscale scores for Cost Factor and Planning & Preparation Factor are calculated as score at follow up minus score at baseline, with positive values indicating an increase in satisfaction) from baseline to follow up.

baseline (12-15 weeks gestation), (35-36 weeks gestation)
Proportion of Women Exceeding Institute of Medicine Gestational Weight Gain Guidelines
時間枠:First prenatal visit (<=15 weeks gestation), last prenatal visit (35+ weeks gestation)

Weight at the first prenatal visit will be subtracted from weight at the last prenatal visit. Women will be categorized as exceeding 2009 Institute of Medicine gestational weight gain guidelines if the difference is > 11.5 kg gain for women with overweight or >9 kg for women with obesity at the first prenatal visit.

First prenatal visit (<=15 weeks gestation), last prenatal visit (35+ weeks gestation)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Gareth Dutton, PhD、University of Alabama at Birmingham
  • 主任研究者:Camille Worthington, PhD、University of Alabama at Birmingham

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年8月9日

一次修了 (実際)

2025年10月14日

研究の完了 (実際)

2025年10月31日

試験登録日

最初に提出

2022年10月25日

QC基準を満たした最初の提出物

2022年10月28日

最初の投稿 (実際)

2022年11月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年10月12日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified individual participant data (IPD) that underlie the results reported in a publication will be made available upon request beginning 9 months and ending 36 months following article publication. The research team will keep a record of all individuals and/or research teams who request and receive a copy of the project data. Interested investigators will be asked to submit a document indicating the specific aims of the analyses, the analytic plan, available resources for completing the proposed project, proposed timeline, and goals (i.e., manuscripts, presentations, and/or grant applications). The PI and research team will review these requests to determine whether the proposed analyses constitute an innovative and significant exploration of the data, whether the proposed team has sufficient resources to complete the request, and whether data will be adequately protected and managed.

IPD 共有時間枠

Data requests can be submitted starting 9 months after publication of results and ending 36 months following article publication.

IPD 共有アクセス基準

Access to IPD stripped of all HIPAA identifiers (except age) for this study can be requested by qualified researchers engaging in independent scientific research whose proposed research has received Institutional Review Board approval, and will be provided following review and approval of a research proposal and timeline, statistical analysis plan, and goals (e.g., manuscripts, presentations, grant applications). The Principal Investigator (PI) and research team will review these requests to determine whether the proposed analyses constitute an innovative and significant exploration of the data, whether the proposed team has sufficient resources to complete the request, and whether data will be adequately protected and managed. Based on institutional policies, execution of a Data Sharing Agreement may be required prior to sharing of IPD. IPD requests can be made to the MPIs at gdutton@uabmc.edu or cschneid@uab.edu.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する